Cartalax

Also known as: Cartilage Peptide Bioregulator, Joint Bioregulator

A bioregulator peptide supporting cartilage health and joint function.

Overview

Cartalax is a synthetic tripeptide from the Khavinson bioregulator family designed to support cartilage and joint health. It may help maintain cartilage integrity and support joint function, particularly in aging or after injury.

Mechanism of Action

Gene regulatory effects on chondrocytes. Proposed to normalize cartilage matrix protein synthesis. May support collagen type II production and reduce degradation.

Pharmacokinetics

Small peptide allows oral/sublingual administration. Tissue-specific effects on cartilage.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Joint Support

Dose

10-20 mg

Frequency

1-2x daily

Duration

10-30 days

Repeat courses as needed

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Joint healing

Synergy: Comprehensive joint and cartilage support

Research Areas

OsteoarthritisJoint HealthCartilage RepairSports InjuriesAging JointsRheumatic Conditions

Key Research Findings

  • 1Improved joint function in osteoarthritis patients
  • 2Support for cartilage matrix maintenance
  • 3Gene expression effects on chondrocytes
  • 4Reduced joint pain scores in studies

Side Effects & Contraindications

Reported Side Effects

  • Generally well-tolerated

Contraindications

  • None well-established

Safety Considerations

Generally well-tolerated. Limited Western clinical data. May be combined with other joint therapies.

Storage Requirements

Store at room temperature

Scientific References

Quick Reference

Sequence
Ala-Glu-Asp
Molecular Weight
~333 g/mol
Half-Life
Short
Bioavailability
Oral/sublingual
Research Stage
clinical phase 2
Administration
Oral or sublingual